The pathophysiology of intratracheal LPS or BLM lung injury mice model after LPS-priming
The pathophysiology of intratracheal LPS or BLM lung injury mice model after LPS-priming
批准号:
22590854
负责人:
TSUSHIMA Kenji
金额:
$2.91万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2010
资助国家:
日本
项目状态:
已结题
起止时间:
2010 至 2012
中文摘要
为了研究肺泡巨噬细胞(AM)在急性肺损伤(ALI)模型启动反应中的潜在作用,我们在第3天用cl2mda -脂质体(耗尽的启动AM)治疗WT小鼠,然后再用IT治疗。到第5天,与耗尽引物的AM组相比,未耗尽引物组表现出支气管肺泡灌洗(BAL)蛋白和BAL细胞的减少。肺组织学显示,非am -贫启动组在第5天损伤几乎完全消退;am缺失组间质增厚和肺实变持续存在。流式细胞术显示,在第0天,cl2mdp脂质体处理组超过90%的AMs被耗尽。与未耗尽AM组相比,缺失AM组在LPS作用后第1天BAL肿瘤坏死因子- α降低,第5天BAL IL-10升高。与启动的WT小鼠相比,il -10缺失小鼠在启动后没有加速肺损伤的消退。这些研究暗示am衍生的IL-10与LPS引发的ALI的加速分解有关。定义与启动相关的机制可以为潜在的ALI新疗法提供重要的见解。
英文摘要
To examine potential roles for alveolar macrophages (AM) in the priming response in model of acute lung injury (ALI), primed WT mice were treated with Cl2MDP-liposome (depleted primed AM) on day -3 followed by IT. By day 5, the non-depleted primed group exhibited reduced bronchoalveolar lavage (BAL) protein and BAL cells compared to depleted primed AM group. Lung histology revealed nearly complete resolution of injury on day 5 in non-AM-depleted primed group; interstitial thickening and lung consolidation persisted in the AM-depleted primed group. Flow cytometry revealed thatat day 0 over 90% of AMs were depleted in the Cl2MDP-liposome treated group. BAL tumor necrosis factor-alpha was lower on day 1 and was higher on day 5 in depleted primed AM group compared to non-depleted primed AM group while BAL IL-10 was higher in non-depleted primed AM group on day 1 after LPS. In contrast to primed WT mice, IL-10-null mice did not exhibit accelerated resolution of lung injury with priming. These studies implicate AM-derived IL-10 in the accelerated resolution of ALI produced by LPS priming. Definition of mechanisms related to priming could provide important insights into potential new therapies for ALI..
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.rmed.2010.05.014
发表时间:
2010-11-01
期刊:
RESPIRATORY MEDICINE
影响因子:
4.3
作者:
[Tsushima, Kenji, Sone, Shusuke, Kubo, Keishi]
通讯作者:
Kubo, Keishi
シンポジウム ALI/ARDS 薬物療法の厳重と将来 抗凝固療法
研讨会 ALI/ARDS 药物治疗的严格性和未来 抗凝治疗
DOI:
--
发表时间:
2010
期刊:
影响因子:
--
作者:
[久米裕昭, 牧野 靖, 東田有智, 千田金吾, 津島健司]
通讯作者:
津島健司
Phase II trial of biweekly paclitaxel and gemcitabine as second-line chemotherapy for non-small cell lung cancer previsously treated with platinum-based chemotherapy.
双周紫杉醇和吉西他滨作为二线化疗用于先前接受铂类化疗的非小细胞肺癌的 II 期试验。
DOI:
--
发表时间:
2011
期刊:
Shinshu Med J
影响因子:
--
作者:
[Kobayashi T, Koizumi T, Yasuo M, Tsushima K, et al.]
通讯作者:
et al.
第3回セミナーALF/ARDS抗凝固療法
第三期ALF/ARDS抗凝治疗研讨会
DOI:
--
发表时间:
2010
期刊:
影响因子:
--
作者:
[田澤立之, 中田光, 津島健司]
通讯作者:
津島健司
第3回セミナー ALI/ARDS抗凝固療法
第三届ALI/ARDS抗凝治疗研讨会
DOI:
--
发表时间:
2010
期刊:
影响因子:
--
作者:
[Yamatoji M, et al, 津島健司]
通讯作者:
津島健司
共 19 条